Ampreloxetine (TD-9855)

Small molecule

Discontinuedsponsor decision

Evidence outlook · program status

Discontinued (2026-03-03), after a negative readout

Theravance Biopharma decided to wind down the ampreloxetine program on 3 March 2026, after the Phase 3 CYPRESS study in neurogenic orthostatic hypotension due to MSA did not meet its primary endpoint. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (4)
Other / comorbidity
NCT04095793 · Theravance Biopharma
2019-09-19 – 2021-11-12 · Symptomatic Neurogenic Orthostatic Hypotension
What this study did
Phase 2 (3)
Other / comorbidity
NCT02705755 · Theravance Biopharma
2017-09-09 – 2018-11-28 · Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension, Pure Autonomic Failure, Parkinson Disease, Hypotension, Orthostatic, Orthostatic Hypotension, Pure Autonomic Failure With Orthostatic Hypotension, Parkinson Disease With Orthostatic Hypotension
What this study did
NCT01693692 · Theravance Biopharma
2012-11 – 2014-04 · Fibromyalgia
What this study did
NCT01458340 · Theravance Biopharma
2011-12 – 2013-11 · Attention-Deficit/Hyperactivity Disorder, ADHD
What this study did
Phase 1 (4)
Other / comorbidity
NCT04200573 · Theravance Biopharma
2020-01-13 – 2021-08-19 · Symptomatic Neurogenic Orthostatic Hypertension, nOH
What this study did
NCT04688632 · Theravance Biopharma
2021-01-18 – 2021-03-26 · Symptomatic Neurogenic Orthostatic Hypertension, nOH
What this study did
NCT03432793 · Theravance Biopharma
2018-02-28 – 2018-04-21 · Drug Drug Interaction (DDI)
What this study did
NCT01924143 · Theravance Biopharma
2013-10 – 2013-12 · ADHD, Fibromyalgia
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, 3 of them ahead of this one.

This drug's own stage for Neurogenic Orthostatic Hypotension: Discontinued. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ampreloxetine (TD-9855): this drugDiscontinuedSmall moleculenorepinephrine transporternot yet graded
NCT05696717: CYPRESS (NCT05696717), primary endpoint change in OHSA composite score at Week 8: result was not statistically significant. missed
NCT03750552: Change From Baseline in Orthostatic Hypotension Symptom Assessment (OHSA) Question #1 Score at Week 4 (Baseline and Week 4): Ampreloxetine -1.69 score on a scale (Standard Error 0.29) | Placebo -1.45 score on a scale (Standard Error 0.293) missed
Droxidopa (Northera)ApprovedSmall moleculenorepinephrine precursorPartial signal
NCT01176240: 306A Efficacy: Change in Orthostatic Hypotension Questionnaire Score (OHQ) (Baseline, Week 8): Droxidopa -2.2 units on a scale (Standard Deviation 2.44) vs Placebo -2.1 units on a scale (Standard Deviation 2.49)
Viloxazine (Qelbree)
Approved(overall)
Small moleculenorepinephrine transporter
Reliable signal(overall)
No reviewed efficacy summary in this indication
Esreboxetine
Phase 3(overall)
Small moleculenorepinephrine transporter
not yet graded(overall)
No reviewed efficacy summary in this indication
Reboxetine
Phase 3(overall)
Small moleculenorepinephrine transporter
Partial signal(overall)
No reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

3 March 2026Topline resultCYPRESS (NCT05696717) Phase 3 did not meet its primary endpoint; programme wound down
Theravance Biopharma, Inc. · Source ↗